{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:01:53Z","timestamp":1740124913239,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Invasive ductal carcinoma (IDC) is often accompanied by ductal carcinoma in situ (DCIS). Whether the DCIS component affects the 21-gene recurrence score (RS) is unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Consecutive ER-positive, HER2-negative, N0\u20131 patients with RS results were included. Patients were divided into pure IDC and IDC with DCIS (IDC\/DCIS) groups. The RS, the expression of its 16 cancer genes and prognosis were compared between IDC and IDC\/DCIS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1458 patients were enrolled, 320 of whom had concomitant DCIS. DCIS component was independently associated with lower RS (<jats:italic>P<\/jats:italic>\u2009=\u20090.038). IDC\/DCIS patients more often had a low-risk RS (<jats:italic>P<\/jats:italic>\u2009=\u20090.018) or intermediate-risk RS (<jats:italic>P<\/jats:italic>\u2009=\u20090.024). Regarding individual genes in the RS panel, Ki67, CCNB1 and MYBL2 in the proliferation group and MMP11 and CTSL2 in the invasion group were significantly lower among IDC\/DCIS patients than pure IDC patients. Among IDC\/DCIS patients, lower RS was independently correlated with a higher DCIS proportion and lower DCIS grade. Within a median follow-up of 31 months, the DCIS component in IDC did not significantly influence prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IDC with DCIS component is associated with a lower 21-gene RS, possibly due to lower expression of proliferation and invasion genes. DCIS proportion and grade independently influenced the 21-gene RS in IDC\/DCIS patients. Due to the relatively short follow-up period and low recurrence rate, the impact of the DCIS component in IDC on prognosis needs further evaluation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-01212-w","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T12:07:16Z","timestamp":1608206836000},"page":"975-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8029","authenticated-orcid":false,"given":"Yufei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-9524","authenticated-orcid":false,"given":"Weiqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-9444","authenticated-orcid":false,"given":"Xiaosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-8666","authenticated-orcid":false,"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2008.18.3103","volume":"27","author":"HM Kuerer","year":"2009","unstructured":"Kuerer, H. M., Albarracin, C. T., Yang, W. T., Cardiff, R. D., Brewster, A. M., Symmans, W. F. et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J. Clin. Oncol. 27, 279\u2013288 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1212_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc2950","volume":"11","author":"V Espina","year":"2011","unstructured":"Espina, V. & Liotta, L. A. What is the malignant nature of human ductal carcinoma in situ? Nat. Rev. Cancer 11, 68\u201375 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1212_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1200\/JCO.1990.8.1.113","volume":"8","author":"R Holland","year":"1990","unstructured":"Holland, R., Connolly, J. L., Gelman, R., Mravunac, M., Hendriks, J. H., Verbeek, A. L. et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J. Clin. Oncol. 8, 113\u2013118 (1990).","journal-title":"J. Clin. Oncol."},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.surg.2009.06.039","volume":"146","author":"AB Chagpar","year":"2009","unstructured":"Chagpar, A. B., McMasters, K. M., Sahoo, S. & Edwards, M. J. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? Surgery 146, 561\u2013567 (2009).","journal-title":"Surgery"},{"key":"1212_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1590\/S0100-879X2002000800008","volume":"35","author":"AF Logullo","year":"2002","unstructured":"Logullo, A. F., Godoy, A. B., Mourao-Neto, M., Simpson, A. J., Nishimoto, I. N. & Brentani, M. M. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. Braz. J. Med. Biol. Res. = Rev. brasileira de. Pesqui. medicas e biologicas 35, 913\u2013919 (2002).","journal-title":"Braz. J. Med. Biol. Res. = Rev. brasileira de. Pesqui. medicas e biologicas"},{"key":"1212_CR6","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00432-019-02930-2","volume":"145","author":"CW Goh","year":"2019","unstructured":"Goh, C. W., Wu, J., Ding, S., Lin, C., Chen, X., Huang, O. et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC\/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J. Cancer Res. Clin. Oncol. 145, 1877\u20131886 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1212_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.breast.2014.01.015","volume":"23","author":"M Dieterich","year":"2014","unstructured":"Dieterich, M., Hartwig, F., Stubert, J., Klocking, S., Kundt, G., Stengel, B. et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Breast 23, 346\u2013351 (2014).","journal-title":"Breast"},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","volume":"102","author":"H Wong","year":"2010","unstructured":"Wong, H., Lau, S., Yau, T., Cheung, P. & Epstein, R. J. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br. J. Cancer 102, 1391\u20131396 (2010).","journal-title":"Br. J. Cancer"},{"key":"1212_CR9","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817\u20132826 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1212_CR10","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726\u20133734 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1212_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2007.15.1068","volume":"26","author":"JA Sparano","year":"2008","unstructured":"Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721\u2013728 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1212_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55\u201365 (2010).","journal-title":"Lancet Oncol."},{"key":"1212_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B. & Senn, H. J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319\u20131329 (2009).","journal-title":"Ann. Oncol."},{"key":"1212_CR14","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206\u20132223 (2013).","journal-title":"Ann. Oncol."},{"key":"1212_CR15","doi-asserted-by":"publisher","first-page":"38706","DOI":"10.18632\/oncotarget.16313","volume":"8","author":"J Wu","year":"2017","unstructured":"Wu, J., Fang, Y., Lin, L., Fei, X., Gao, W., Zhu, S. et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget 8, 38706\u201338716 (2017).","journal-title":"Oncotarget"},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/annonc\/mdv478","volume":"26","author":"S Gourgou-Bourgade","year":"2015","unstructured":"Gourgou-Bourgade, S., Cameron, D., Poortmans, P., Asselain, B., Azria, D., Cardoso, F. et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in cancer trials). Ann. Oncol. 26, 2505\u20132506 (2015).","journal-title":"Ann. Oncol."},{"key":"1212_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005\u20132014 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1212_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4143\/crt.2013.223","volume":"47","author":"MH Lee","year":"2015","unstructured":"Lee, M. H., Han, W., Lee, J. E., Kim, K. S., Park, H., Kim, J. et al. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res. Treat. 47, 208\u2013214 (2015).","journal-title":"Cancer Res. Treat."},{"key":"1212_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","volume":"105","author":"LJ Solin","year":"2013","unstructured":"Solin, L. J., Gray, R., Baehner, F. L., Butler, S. M., Hughes, L. L., Yoshizawa, C. et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 105, 701\u2013710 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"1212_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jclinpath-2019-205939","volume":"73","author":"M Toss","year":"2020","unstructured":"Toss, M., Miligy, I., Gorringe, K., Mittal, K., Aneja, R., Ellis, I. et al. Prognostic significance of cathepsin V (CTSV\/CTSL2) in breast ductal carcinoma in situ. J. Clin. Pathol. 73, 76\u201382 (2020).","journal-title":"J. Clin. Pathol."},{"key":"1212_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.humpath.2009.08.027","volume":"41","author":"LO Gonzalez","year":"2010","unstructured":"Gonzalez, L. O., Junquera, S., del Casar, J. M., Gonzalez, L., Marin, L., Gonzalez-Reyes, S. et al. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum. Pathol. 41, 980\u2013989 (2010).","journal-title":"Hum. Pathol."},{"key":"1212_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/his.13956","volume":"75","author":"N Eiro","year":"2019","unstructured":"Eiro, N., Cid, S., Fernandez, B., Fraile, M., Cernea, A., Sanchez, R. et al. MMP11 expression in intratumoral inflammatory cells in breast cancer. Histopathology 75, 916\u2013930 (2019).","journal-title":"Histopathology"},{"key":"1212_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/bcr65","volume":"2","author":"MJ Duffy","year":"2000","unstructured":"Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E. & O\u2019Higgins, N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252\u2013257 (2000).","journal-title":"Breast Cancer Res."},{"key":"1212_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10549-019-05195-y","volume":"175","author":"AF de Groot","year":"2019","unstructured":"de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V., Dekker-Ensink, N. G. et al. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 175, 605\u2013615 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"1212_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clbc.2013.04.005","volume":"13","author":"J-Y Kim","year":"2013","unstructured":"Kim, J.-Y., Han, W., Moon, H.-G., Park, I.-A., Ahn, S. K., Kim, J. et al. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Clin. breast cancer 13, 385\u2013391 (2013).","journal-title":"Clin. breast cancer"},{"key":"1212_CR26","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1200\/JCO.2001.19.8.2263","volume":"19","author":"N Bijker","year":"2001","unstructured":"Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C. et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 19, 2263\u20132271 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1212_CR27","first-page":"527","volume":"10","author":"SG Wu","year":"2018","unstructured":"Wu, S. G., Zhang, W. W., Sun, J. Y. & He, Z. Y. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance. Epidemiol., End. Results Database Anal. Cancer Manag. Res. 10, 527\u2013534 (2018).","journal-title":"Epidemiol., End. Results Database Anal. Cancer Manag. Res."},{"key":"1212_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","volume":"152","author":"E Rakovitch","year":"2015","unstructured":"Rakovitch, E., Nofech-Mozes, S., Hanna, W., Baehner, F. L., Saskin, R., Butler, S. M. et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res. Treat. 152, 389\u2013398 (2015).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01212-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T01:02:45Z","timestamp":1639702965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01212-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,2]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01212-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study was reviewed and approved by independent ethics committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The study was performed in accordance with the Declaration of Helsinki, and informed consent was obtained from each patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets used and analysed during this study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was funded by the National Natural Science Foundation of China (No. 81772797), Shanghai Municipal Education Commission\u2014Gaofeng Clinical Medicine Grant Support (No. 20172007) and Ruijin Hospital, Shanghai Jiao Tong University School of Medicine\u2014\u201cGuangci Excellent Youth Training Program\u201d (No. GCQN-2017-A18).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}